Sanofi (SNYNF)
Market Cap | 120.80B |
Revenue (ttm) | 54.03B |
Net Income (ttm) | 5.03B |
Shares Out | n/a |
EPS (ttm) | 4.00 |
PE Ratio | 24.04 |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 1,200 |
Open | 99.03 |
Previous Close | 96.19 |
Day's Range | 95.81 - 99.03 |
52-Week Range | 90.45 - 119.65 |
Beta | 0.42 |
Analysts | n/a |
Price Target | n/a |
Earnings Date | Jan 30, 2025 |
About Sanofi
Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products. In addition, it offers poliomyelitis, pertussis, and hib pediatric ... [Read more]
Financial Performance
In 2023, Sanofi's revenue was 46.03 billion, an increase of 1.42% compared to the previous year's 45.39 billion. Earnings were 5.40 billion, a decrease of -35.49%.
Financial numbers in EUR Financial StatementsNews
Sanofi’s chief digital officer says remote work means employees lose the ‘serendipity’ needed to innovate
"I think we were contrarians,” Sanofi's chief digital officer Emmanuel Frenehard told Fortune. “I think the contrarians are becoming the norm.”
Sanofi CEO Paul Hudson takes inspiration from ‘Fight Club’ to get his team hooked on AI
Hudson says many CEOs are scared of AI, comparing it to The Terminator’s John Connor traveling back in time to stop the rise of the machines.
Sanofi (SNY) to Build Modular Vaccine Factory in Singapore
Sanofi (SNY) to Build Modular Vaccine Factory in Singapore
Pharma giant Sanofi opens $595 million vaccine facility in Singapore to boost preparedness for potential pandemics
It will contribute about 200 skilled jobs to the city-state, and will be fully operational by mid-2026.
Sanofi Boosts Preparedness With $600 Million Singapore Plant
Sanofi SA added a new plant in Singapore to make vaccines and other medicines, as the French pharmaceutical group seeks to bolster preparedness for emergencies, including potential pandemics.
Sanofi appoints new leader for Africa and Egypt
Adriens leadership will be instrumental in Egypt in addressing healthcare challenges and opportunities and across Africa
Emcure Pharmaceuticals stock surges 5% as Kotak Securities upgrade to ‘Buy’ rating
Emcure Pharmaceuticals shares soared over 5% after Kotak Securities upgraded the stock to a “Buy” rating, raising the target price to ₹1,680. The brokerage cited robust growth potential, driven by a s...
Sanofi plans to change hospital drug-discount program, WSJ reports
French drugmaker Sanofi plans to change its policy on how it gives discounts to certain U.S. hospitals that serve low-income and uninsured patients, the Wall Street Journal reported on Friday.
Recordati CEO sees 'substantial opportunity' in Sanofi drug purchase
Rob Koremans, CEO of Italian pharmaceutical company Recordati, weighs in on the company's purchase of Sanofi's rare immune disorder drug, Enjaymo.
Recordati CEO sees 'substantial opportunity' in Sanofi drug purchase
Rob Koremans, CEO of Italian pharmaceutical company Recordati, weighs in on the company's purchase of Sanofi's rare immune disorder drug, Enjaymo.
Vaccine stocks hit by Robert Kennedy Jr nomination
GSK, Sanofi and Moderna shares all sink after Donald Trump chooses vaccine sceptic as top US health official
European And US Vaccine Stocks Are Under Pressure - Here's WHy
Some large European and U.S. vaccine maker stocks have fallen in reaction to Robert F. Kennedy Jr.'s nomination to lead the Department of Health and Human Services.
Regeneron, Sanofi say resubmitted application to expand Dupixent label accepted in U.S.
European Stocks Fall as Traders Trim Rate-Cut Bets; Sanofi Drops
European stocks fell as traders pared back expectations for an interest-rate cut by the Federal Reserve in December after cautious comments from Chair Jerome Powell.
Press Release: Dupixent sBLA accepted for FDA review for the treatment of chronic spontaneous urticaria
Dupixent sBLA accepted for FDA review for the treatment of chronic spontaneous urticaria Resubmission includes new pivotal data which confirm Dupixent significantly reduced itch and hive activity More...
Telangana attracted 141 life sciences investments worth Rs 36,000 crore in 1 year: Sridhar Babu
Telangana has secured 141 life sciences investments totaling nearly ₹36,000 crore in the past year, creating thousands of jobs. Major players like Cigna, Amgen, and Sanofi are establishing GCCs and in...
Viking Fund Management Sells Big Oil Stocks In Q3, Cuts Tesla Position In Half, Adds To Largest Position Broadcom
A new 13F filing from Viking Fund Management reveals which companies the fund bought and sold in the third quarter, including exiting some oil companies ahead of the 2024 election. Third Quarter Exits...
Press Release: Sarclisa recommended for EU approval by the CHMP to treat transplant-ineligible newly diagnosed multiple myeloma
Sarclisa recommended for EU approval by the CHMP to treat transplant-ineligible newly diagnosed multiple myeloma Recommendation based on IMROZ phase 3 study demonstrating Sarclisa in combination with ...
Regeneron/Sanofi's Dupixent Approval Signals Major Treatment Breakthrough For Smokers' Lung Disease
After years of limited advancements in chronic obstructive pulmonary disease (COPD) treatment, patients now have new options. Regeneron Pharmaceuticals Inc (NASDAQ: REGN) and Sanofi SA’s (NASDAQ: SNY...
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Third Quarter 2024
― Patient enrollment and site activation progressing in Phase 1b PIONEER trial of pociredir in sickle cell disease (SCD) ― ― Ended the third quarter of 2024 with $257.2 million in cash, cash equivalen...
Healx announces agreement with Sanofi to seek new rare disease indications for compound using AI drug discovery platform
CAMBRIDGE, England--(BUSINESS WIRE)--Healx, an AI-enabled, clinical-stage biotech company specialising in rare diseases, today announced it will use a Sanofi compound to identify new disease indicatio...
RFK Jr.'s Impact on Healthcare Policy: Investors Weigh Risks and Opportunities
Emily Field from Barclays and Lance Wilks share insights on how RFK Jr.'s influence could affect stocks in the pharmaceutical and healthcare sectors, including companies like GSK, Sanofi, and Novo Nor...
Sanofi: Diverse Drug Portfolio And Future Pipeline, 4% Dividend Yield Looks Attractive
CEO of pharma giant Sanofi says businesses should stop ‘AI washing’
Some companies are overselling AI without thinking through the risks, according to Paul Hudson
The Accumulus Platform Powers Sanofi's Submissions to Multiple Regulators Around the World
BURLINGAME, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Accumulus Synergy, Inc. (“Accumulus”), is revolutionizing the scalability of reliance pathways, enabling a recent submission from Sanofi to multip...